H1N1 (Swine Flu) Prevention: Antivirals, Vaccination, and Hygiene

Influenza A(H1N1)pdm09 circulates seasonally. Prevention combines pharmaceutical and non-pharmaceutical measures.

Antiviral Prophylaxis

  • Oseltamivir (Tamiflu): 75 mg daily × 7-10 days post-exposure; 75 mg daily during outbreak in closed settings (nursing homes).
  • Zanamivir (Relenza): 10 mg inhaled daily × 7-10 days. Not for asthma/COPD (bronchospasm risk).
  • Baloxavir marboxil (Xofluza): Single dose post-exposure prophylaxis (approved ≥12 years).

Not substitutes for vaccination. Resistance emerges with monotherapy; use judiciously.

Vaccination

  • Annual quadrivalent inactivated (IIV) or recombinant (RIV) or live attenuated (LAIV) vaccine.
  • Updated for circulating strains (WHO GISRS).
  • Best timing: September-October (before peak).
  • Priority: ≥6 months, especially pregnant, chronic disease, immunocompromised, healthcare workers.

Non-Pharmaceutical Interventions

  • Hand hygiene (soap/water or ≥60% alcohol sanitizer).
  • Respiratory etiquette (mask, tissue, elbow cough).
  • Stay home when febrile/respiratory symptoms.
  • Ventilation, air filtration (HEPA, UVGI).
  • Avoid crowded indoor spaces during peak.

Treatment (If Infected)

Antivirals within 48h of onset reduce duration ~1 day and complications. High-risk patients: treat regardless of duration.

Layered protection works best.

Viral Infections - Related Articles